Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes by Tyring, Stephen et al.
Arch Gynecol Obstet (2007) 275:1–3 
DOI 10.1007/s00404-006-0234-z
123
REVIEW
Single-day therapy: an expert opinion on a recent development 
for the episodic treatment of recurrent genital herpes
Stephen Tyring · Gary Richwald · Kamal Hamed 
Received: 21 July 2006 / Accepted: 7 August 2006 / Published online: 7 September 2006
© Springer-Verlag 2006
Abstract One common method for treating recurrent
genital herpes outbreaks is 3–5 day episodic therapy
with nucleoside analogues. However, since maximum
viral replication occurs within 24 h after the onset of
symptoms, short-term patient-initiated episodic ther-
apy started at prodromal onset or at the Wrst appear-
ance of lesions in patients without a prodrome may
represent an important option. In a recent randomized
trial, single-day famciclovir treatment decreased lesion
healing time and the duration of pain and other symp-
toms by approximately 2 days compared to placebo,
and prevented progression to a full outbreak in almost
one in four patients. Because single-day treatment is
more convenient than traditional therapies, it may lead
to improved patient compliance and better overall
management of recurrent genital herpes outbreaks.
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Introduction
Recurrent genital herpes outbreaks are predominantly
caused by herpes simplex virus type 2 (HSV-2),
although the incidence of genital herpes caused by her-
pes simplex virus type 1 (HSV-1) is rising due to chang-
ing attitudes about oral-genital sexual behavior [10].
Approximately one in four adults in the United States
is seropositive for HSV-2 [7], an incurable infection
that initially enters the body through mucous mem-
branes or abraded skin. Once primary infection has
occurred, the virus remains dormant in the dorsal root
ganglia, where it can reactivate to cause uncomfort-
able, recurrent outbreaks [20].
HSV-2 infection is somewhat more prevalent in
women than in men [7], and can have a profound psy-
chological impact as well as physical repercussions,
resulting in a decrease in measures of quality of life.
The fear of spreading the infection can result in low-
ered self-esteem or sexual desire and, less commonly,
social phobia and depression [6]. In addition, patients
with genital herpes have a signiWcantly increased risk
of acquiring human immunodeWciency virus (HIV) [8].
Episodic treatment for genital herpes
Although there is no cure for HSV-2 infection, patients
have two treatment options: treating outbreaks as they
occur (episodic therapy), or attempting to prevent
future outbreaks (suppressive therapy). Suppression
with daily oral antivirals may be most appropriate for
patients with frequent or uncomfortable recurrences
and to reduce genital herpes transmission to sexual
partners [4]. Although suppressive therapy is eVective,
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one quarter to one half of patients on suppressive ther-
apy have at least one recurrence per year [5, 14].
Although episodic treatment has not been proven to
reduce the risk of transmission, it still remains an
important option for patients who do not want to take
daily suppressive therapy, are not concerned about the
frequency of recurrences, or are not sexually active.
The best method for administering episodic therapy is
to make medication readily available to patients to
self-administer at the Wrst onset of symptoms or lesions
[16]. This type of patient-initiated episodic therapy has
been successfully used in previous clinical trials of
recurrent genital herpes [13, 15]. The ability to treat
recurrences sooner may also help decrease the dura-
tion of an outbreak or halt progression to a full out-
break [9, 13, 15, 19]. This expert opinion will examine
the results from a recently published clinical trial about
patient-initiated, single-day oral antiviral therapy (fam-
ciclovir) for recurrent genital herpes [2] and compare
its eYcacy with data from currently available therapies.
Treatment of recurrent genital herpes with oral 
antivirals
Patients with recurrent episodes of genital herpes often
experience such prodromal symptoms as itching, tin-
gling, burning, and pain, with papules and vesicles typi-
cally forming 12–24 h after onset of these symptoms
[3]. Maximum HSV-2 concentration and lesion pain
usually occur within the Wrst 24 h of onset of these pro-
dromal symptoms [3]. Under the assumption that one
can extrapolate from the pathogenesis of herpes labi-
alis [17], it is thought that the most eVective way to
treat recurrent genital herpes with antiviral therapy
would be within the Wrst 24 h after the onset of clinical
symptoms, when viral replication is highest [16]. Oral
antivirals, acting as nucleoside analogues enter
infected cells and bind to viral thymidine kinase, result-
ing in their phosphorylation. After the antivirals are
further phosphorylated by cellular enzymes, they com-
pete with nucleosides to bind to the viral DNA poly-
merase, resulting in polymerase inactivation and a
decrease in viral replication [16].
Although topical acyclovir was initially used to treat
recurrent genital herpes, it has since been proven
ineVective and is no longer recommended [1,  12].
Today, the most commonly prescribed drugs are the
oral antivirals acyclovir, valacyclovir, and famciclovir.
Acyclovir is approved for 5-day episodic treatment,
although a 2-day regimen has been shown to be eVec-
tive [13, 19]. Acyclovir is eVective, but its poor bioavail-
ability requires more frequent dosing. Valacyclovir, a
prodrug of acyclovir, has a higher bioavailability than
acyclovir and has been approved for 3-day episodic
treatment [9, 14]. Famciclovir, a prodrug of penciclovir,
is currently indicated for 5-day treatment [11, 15]. The
high bioavailability of famciclovir (77%) and the rapid
onset of viral replication in recurrent genital herpes sug-
gested that this medication would be eYcacious in an
even shorter single-day treatment regimen.
Data from single-day famciclovir clinical trial
A clinical trial was performed to assess whether single-
day famciclovir was eVective in treating recurrent geni-
tal herpes in immunocompetent individuals [2]. The
329 study participants experiencing a recurrence of
genital herpes were predominately female (71%) and
48% had had more than six recurrences in the preced-
ing year. Participants were given a single day of famci-
clovir 1,000 mg bid or matching placebo and were
instructed to take the medication within 6 h of the
onset of prodromal symptoms and/or genital herpes
lesions during their next recurrence. The trial results
showed that a single-day regimen of famciclovir signiW-
cantly decreased lesion-healing time and signiWcantly
reduced time to resolution of all symptoms by 2 days,
as compared to placebo. Famciclovir also halted the
progression to a full genital herpes outbreak in almost
one in four patients. Adverse events were of mild-to-
moderate intensity and were similar to the adverse
events experienced by the placebo group.
Although no head-to-head studies have been con-
ducted between single-day famciclovir and other oral
antivirals, patients who received single-day famciclovir
experienced eVects similar to those seen in previous
clinical trials of traditional longer-term therapies
(Table 1) [2,  9,  13,  15,  18,  19]. Single-day therapy
appears to inhibit viral replication enough to signiW-
cantly reduce both symptoms and the tissue damage
characteristic of a full outbreak, preventing progres-
sion to a full recurrence in some cases.
Conclusion
The rapid onset of viral replication in recurrent genital
herpes suggests that a shorter course of therapy would
be as eYcacious as traditional treatments. Patient-initi-
ated single-day therapy could prove helpful for obste-
tricians/gynecologists who treat patients with genital
herpes, as it may provide a more convenient option for
treating the disease, and could help to promote patient
compliance. High bioavailability, ease of use, and theArch Gynecol Obstet (2007) 275:1–3 3
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added beneWt of preventing progression to a full geni-
tal herpes outbreak in some patients make famciclovir
an excellent candidate for single-day patient-initiated
episodic therapy.
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Table 1 EVectiveness of oral antivirals in clinical trials of episodic treatment for genital herpes
a Mean time to healing
b P values correspond to both valacyclovir versus placebo and acyclovir versus placebo
NS = Not signiWcant
Drug Treatment regimen Median time (days) to lesion 
healing (treatment vs control)
Percent of aborted episodes
(treatment vs control)
Acyclovir [13, 19] 800 mg tid £ 2 days versus placebo
200 mg 5 times daily £ 5 days versus placebo
4.0 versus 6.0 (P = .001) 
5.7 versus 7.2a (P · .001)
27.0 versus 10.6% (P = .029)
Was not performed
Valacyclovir [9, 18] 500 mg bid £ 3 days versus 500 mg bid £ 5 days
1,000 mg bid £ 5 days versus 200 mg acyclovir
5 times daily £ 5 days versus placebo
4.4 versus 4.7 (P =N S )
4.8 versus 4.8 versus 6.0 
(P < .001)b
25.4 versus 26.6% (P =N S )
25.9 versus 24.8 versus 19.8% 
(P =N S )
Famciclovir [2, 15] 1,000 mg bid £ 1 day versus placebo
125 mg bid £ 5 days versus placebo
4.3 versus 6.1 (P < .001)
3.8 versus 4.8 (P < .001)
23.3 versus 12.7% (P = .003)
Was not performed